Cat. No. 3542
Chemical Name: 5-Chloro-N-[(1S,2R)-2-hydroxy-3-(me
Biological ActivitySelective glycogen phosphorylase inhibitor [IC50 values are 0.017 and 0.034 μM against human skeletal muscle glycogen phosphorylase a (huSMGPa) and liver glycogen phosphorylase a (huLGPa) respectively]. Antihyperglycemic agent.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Suh et al (2007) Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide). J.Pharmacol.Exp.Ther. 321 45. PMID: 17251391.
Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation site of the enzyme. Br.J.Pharmacol. 149 775. PMID: 17016495.
Baker et al (2005) Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54 2453. PMID: 16046314.
If you know of a relevant reference for this product please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CP 316819, supplier, glycogen, phosphorylase, inhibitors, inhibits, antihyperglycemic, antihyperglycaemic, transferases, carbohydrate, metabolism, CP316819, Tocris Bioscience, Phosphorylase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent cholesteryl ester transfer protein (CETP) inhibitorPerhexiline maleate
Carnitine palmitoyltransferase 1 and 2 (CPT1/2) inhibitorMS 023 dihydrochloride
Potent and selective type I PRMT inhibitor
April 1 - 5, 2017
Washington, D.C., USA